1 / 6

The antibiotic market is a >$30 billion market worldwide

The antibiotic reality. The antibiotic market is a >$30 billion market worldwide The antibiotic pipeline is as empty as it has been since the discovery of antibiotics (97% of antibiotics in development are analogs of existing drugs) Antibiotic resistance has emerged as a major challenge

jafari
Download Presentation

The antibiotic market is a >$30 billion market worldwide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The antibiotic reality The antibiotic market is a >$30 billion market worldwide The antibiotic pipeline is as empty as it has been since the discovery of antibiotics (97% of antibiotics in development are analogs of existing drugs) Antibiotic resistance has emerged as a major challenge in public and personal health The search for single “blockbuster” broad-spectrum antibiotics is both medically and ecologically foolish

  2. The antibiotic crisis: MRSA

  3. The new antibiotic landscape • The search for single “blockbuster” broad-spectrum antibiotics is medically, ecologically and financially untenable. • Origin is committed to the design of effective • narrow spectrum antimicrobials that: • Specifically target pathogenic organisms • Reduce the emergence of resistance • Leverage developments in diagnostics • and personalized medicine

  4. Bacteriocin Diversity Bacteriocins May be universally present in Bacteria, certainly prevalent E. coli - colicins P. aeruginosa - pyocin B. subtilis - subtilin S. epidermis - epidermin L. brevis - brevicin Archaeacins Universally present

  5. “…pitted against microbial genes we have mainly our wits.”Joshua Lederberg Ia E9 Our leads derive from a family of naturally-occurring antimicrobials, the bacteriocins Ubiquitous Specific and targetable Nontoxic to vertebrates Modifiable and patentable

  6. 3 billion years of R&D Yr 0 Yr 7 Yr 15-20 For additional information, contact: Dr. Robert Dorit or Dr. Margaret Riley origin.antimicrobials@gmail.com Post Market FDA Discovery Animal Trials Phase II Conventional antibiotics Phase III Preclinical Phase I Yr 0 Yr 2 Post Market FDA Animal Trials Phase II Discovery Phase III Preclinical Phase I The lead to bedside pipeline

More Related